Will Another Alzheimer’s Disease Drug Bite the Dust After Lilly’s Latest Results?

1 min read

There’s a pressing need for safe and effective treatments for Alzheimer’s disease. However, there haven’t been many successes after years of research and development. Eli Lilly (NYSE: LLY) recently became the latest to disappoint with mixed results from a phase 2 study of donanemab. In this Motley Fool Live video recorded on March 17, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not yet another Alzheimer’s disease drug could bite the dust after Lilly’s results.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

21Vianet Group Inc (VNET) Q4 2020 Earnings Call Transcript

Next Story

4 Insane Assumptions Embedded in Cathie Wood’s New Tesla Target

Latest from Blog